![]() |
|
|
Vol. 29, Issue 2, 103-110, February 2001
Departments of Internal Medicine (J.T.L., R.S., S.A.) and
Biostatistics (J.J.G.), University of Texas Medical Branch, Galveston,
Texas
P-glycoprotein (Pgp) mediates drug accumulation defects in
malignant cells in vitro. It confers resistance to multiple drugs including paclitaxel, an agent useful in treating malignancies including acute leukemia. Pgp-mediated drug resistance appears to be
due to primary active drug-transport as well as other effects on
membrane permeability, but the relative contribution of each is
unclear. Flow cells are useful for differentiating transport-mediated efflux from altered membrane permeability, but their utility is limited
to attached cells. We developed a novel flow cell to study drug efflux
kinetics in suspension culture cells and examined paclitaxel efflux in
resistant CEM/VLB100 leukemia cells, which overexpress Pgp, compared
with its sensitive CEM parent line. Paclitaxel efflux from both cell
lines was described by bi-exponential kinetics. The predominant initial
rapid component increased linearly with paclitaxel concentration,
consistent with passive efflux, and was faster in CEM/VLB100 than CEM
cells. The slow terminal component of efflux was also more rapid for
CEM/VLB100 than CEM, and was saturable
(Vmax= 9.1 ± 1.1 versus 3.5 ± 0.3 pmol/min/107 cells, respectively) at a lower paclitaxel
concentration than the parental CEM cells
(km = 63 ± 46 nM versus 144 ± 56 nM, respectively). In CEM/VLB100 cells, this saturable component
was inhibited by verapamil and was temperature-sensitive, consistent
with Pgp-mediated transport. Verapamil also inhibited the rapid
component of efflux, suggesting additional effects on membrane
permeability. Our studies show that the present technique is useful for
studying drug transport and that effects of Pgp on membrane
permeability contribute significantly to the net drug-accumulation defect.
This article has been cited by other articles:
![]() |
S. S. Singhal, J. Singhal, S. Yadav, S. Dwivedi, P. J. Boor, Y. C. Awasthi, and S. Awasthi Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1) Cancer Res., May 1, 2007; 67(9): 4382 - 4389. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Stuckler, J. Singhal, S. S. Singhal, S. Yadav, Y. C. Awasthi, and S. Awasthi RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non-Small Cell Lung Cancer Cancer Res., February 1, 2005; 65(3): 991 - 998. [Abstract] [Full Text] [PDF] |
||||